designed to maximize efficacy, improve safety and enhance compliance.

Proven
Proven efficacy with IV Iloprost
Potent
Most potent PAH treatment on a molar basis
Smallest
Compatible with the smallest, most reliable pump available
Fewer refills
Less frequent refills/maintenance than any other delivery system

PulmoProst® will Redefine the Management of Pulmonary Arterial Hypertension (PAH)

Led by a dynamic and proven team of pharmaceutical and biotechnology industry executives along with leading scientists and physicians, Infusyn is redefining the management of PAH – a $6 billion market.

Our potential lead candidate, PulmoProst™ promises to optimize treatment and improve outcomes in PAH. Infusyn has completed a Special Protocol Assessment (SPA) with the US FDA.

Represents an unmet need with a considerable market opportunity

PAH is a rare disease with a prevalence of ~100,000 patients in the US

  • There is no known cure
  • PAH is a progressive and relentless disease
  • Survival is 2 to 3 years without treatment and 5 to 7 with treatment

Despite availability of several effective agents, there's a considerable unmet medical need

  • Mortality remains greater than many cancers

Prostacyclin agonists (including iloprost) are agents of choice, yet are used sparingly due to suboptimal delivery

  • All treatment guidelines recommend prostacyclin agonists, but only IV prostacyclin therapy is known to improve survival rather than just symptoms
  • Constant subcutaneous IV infusions impair quality of life and have substantial negative risks, including infection, challenging drug preparation/delivery systems, and infusion site pain
  • Inhaled and oral delivery produces subtherapeutic levels and reduce quality of life with frequent dosing (4-9 doses/day) which reduces compliance. AEs limit the ability to deliver optimal doses. Nonetheless, prostacyclin/analogue sales total ~$2.1BB
  • ~50% of PAH patients who succumb to the disease never receive IV therapy